Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...
10x Genomics (NASDAQ:TXG) just reported results for the first quarter of 2024. 10x Genomics reported earnings per share of -50 cents. This met the analyst estimate for EPS of -50 cents.
10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.
10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...
10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...
10x Genomics Inc (NASDAQ:TXG) launched major new products across all three platforms, receiving a tremendous customer response. The company introduced new products in the single-cell portfolio ...
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.
The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) ...